Prostate Cell News 10.11 March 29, 2019 | |
![]() | |
| |
TOP STORYScientists evaluated farnesyl diphosphate synthase (FDPS) expression and its cancer-associated phenotypes using in vitro and in vivo methods in PTEN-deficient and sufficient human and mouse prostate cancer cells and tumors. [Oncogene] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers demonstrated that loss of latexin (LXN) was highly expressed in normal prostate luminal cells but downregulated in high Gleason grade cancers. LXN protein was both cytosolic and secreted by prostate cells and expression was directly and potently upregulated by all-trans retinoic acid. [Sci Rep] Full Article The distribution of engrailed-2 (EN2) protein in cells was evaluated using immunofluorescence with a set of antibodies raised against overlapping epitopes across the protein, and through the use of an EN2-GFP construct. MX2 expression in primary prostate tumors was evaluated using immunohistochemistry. [Sci Rep] Full Article The expression of total signal transducer and activator of transcription 3 (tSTAT3), phosphorylated STAT3 (pSTAT3)727, and pSTAT3705 was scored in the nuclei and cytoplasm of prostatic gland epithelial cells in two tissue microarrays of paraffin‐embedded prostatic tissue. [Prostate] Full Article Scientists used both LNCaP, and PC3 and PC3‐androgen receptor cells as a model system and assessed the effects of nimotuzumab on epithelial-mesenchymal transition (EMT) in vitro and in vivo. The EMT makers were detected by immunohistochemistry, qRT‐PCR and Western blot. MTT, wound healing assay, and transwell assay were used to measure cell viability, migration, and invasion, respectively. [IUBMB Life] Abstract Combination of Cabazitaxel and p53 Gene Therapy Abolishes Prostate Carcinoma Tumor Growth Investigators developed the AdRGD-PGp53 vector which offered autoregulated expression of p53, resulting in enhanced tumor cell killing in vitro and in vivo. They combined AdRGD-PGp53 along with the chemotherapy drugs used in the clinical treatment of prostate carcinoma, mitoxantrone, docetaxel, or cabazitaxel. [Gene Ther] Abstract Researchers reported that lysine-specific histone demethylase 5C (KDM5C) was highly expressed in prostate cancer and castration-resistance prostate cancer (CRPC) specimens, and the high expression promoted CRPC cell proliferation through repressing phosphatase and tensin homolog (PTEN) gene epigenetically. [Biomed Pharmacother] Full Article | Graphical Abstract Investigators evaluated raloxifene effects on LNCaP prostate tumor cells modulating the activity of GPER1/GPR30 receptors. [J Pharm Pharmacol] Abstract Tumor-Derived Extracellular Vesicles Require β1 Integrins to Promote Anchorage-Independent Growth Using a cell line-based genetic rescue and an in vivo prostate cancer (PrCa) model, researchers showed that gradient purified small extracellular vesicles from either cancer cells or blood from tumor-bearing TRAMP mice promoted anchorage-independent growth of PrCa cells. [iScience] Abstract | Graphical Abstract | Full Article Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News. | |
| |
REVIEWSEmerging Therapeutic Targets for Patients with Advanced Prostate Cancer The authors discuss novel targets and agents, studied preclinically and now being validated in clinical trials, including poly ADP-ribose polymerase, enhancer of zeste homologue 2, hedgehog pathway, MDM2/p53, and tyrosine kinase inhibitors. [Cancer Treat Rev] Abstract Visit our reviews page to see a complete list of reviews in the prostate cell research field. | |
| |
INDUSTRY NEWSAnixa Biosciences, Inc. announced that the Hunter Holmes McGuire VA Medical Center located in Richmond, VA has joined its ongoing prostate cancer Cchek™ study. [Anixa Biosciences, Inc.] Press Release Arvinas, Inc. announced the initiation of patient dosing in its Phase I clinical trial of ARV-110, the company’s oral androgen receptor (AR)-targeted PROTAC™ protein degrader. [Arvinas, Inc.] Press Release BioXcel Therapeutics, Inc. announced that it has filed a Clinical Trial Application with the UK health authorities for its lead immuno-oncology asset, BXCL701, an orally-available small molecule immune-modulator with dual mechanisms of action, in combination with pembrolizumab, a checkpoint inhibitor, in tNEPC. [BioXcel Therapeutics, Inc.] Press Release ESSA Pharma Inc. announced the nomination of EPI-7386 as the lead clinical candidate for the treatment of metastatic castration-resistant prostate cancer. [ESSA Pharma Inc.] Press Release | |
| |
POLICY NEWSUniversity Fights Restrictive Indiana Law on Fetal Tissue Research A three-judge panel of the Seventh U.S. Circuit Court of Appeals overturned a lower court decision that an Indiana law criminalizing much fetal tissue research is unconstitutionally vague. The ruling moves such work closer to being a felony in the Hoosier State. It’s the most significant court decision yet on laws recently passed in at least seven states that restrict research on tissue from elective abortions. [ScienceInsider] Editorial NIH May Bar Peer Reviewers Accused of Sexual Harassment The National Institutes of Health (NIH) in Bethesda, Maryland, reminded the research community this week that the agency can—and sometimes does—bar scientists accused of sexual harassment from serving as peer reviewers. [ScienceInsider] Editorial
| |
EVENTSNEW Advanced Prostate Cancer Consensus Conference (APCCC) 2019 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Investigator – Genitourinary Medical Oncology (MD Anderson Cancer Center) Postdoctoral Position – Prostate Cancer (UT Health San Antonio) Postdoctoral Position – Microenvironment & Cancer (Brigham and Women’s Hospital) Research Assistant II – Cancer Biology (MD Anderson Cancer Center) Senior Computational Biologist – Molecular Oncology (Cancer Research UK Manchester Institute) Postdoctoral Positions – Stem Cell and Cancer Biology (Columbia University Irving Medical Center) Postdoctoral Fellow – Cancer Biology (Thomas Jefferson University) Postdoctoral Position – Prostate Cancer (University of Trento) Postdoctoral Fellow – Prostate Cancer & Stem Cell Biology (City of Hope) Postdoctoral Fellow – Cancer Immunotherapy (University of Notre Dame) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|